1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Third Panel III) Circulation 2002; 106: 3143–421.
2. Diagnostics and correction of a lipid exchange with the purpose of prevention and atherosclerosis treatment. Russian guidelines (Vth ed.) M 2012. Committee of Russian Cardiology Society experts. Russ J Cardiol 2012; 4: 32 р. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). М 2012. Комитет экспертов РКО. Российский кардиологический журнал 2012; 4 (Приложение № 1): 32 с.
3. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109: 2–7.
4. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363–79.
5. Kwiterovich PO, Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002; 90 (8A): 30i-47.
6. Kathiresan S, Orvos JD, Sullivan LM, et al. Increased small low density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2005; 113: 20–9.
7. Toft-Petersen AP, Tilsted HH, Aaroe J, et al. Small dense LDL particles – a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. Lipids Health Dis 2011; 10: 21–7.
8. Koba S, Yokota Y, Hirano T, et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 2008; 15 (5): 250–60.
9. Oravec S., Dukat A., Gavornik P., et al. Atherogenic normolipidemia – a new phenomenon in the lipoprotein profile of clinically healthy subjects. Neuro Endocrinol Lett 2011; 32 (3): 317–321.
10. Blankstein R, Budoff MJ, Shaw LJ, et al. Predictors of coronary heart disease events among asymptomatic persons with low density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis). JACC 2011; 58: 364–74.
11. Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 1999; 83: 13F-6.
12. Kannel WB, Vassan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24 (4): 345–50.
13. Koba S, Hirano T, Kondo T, et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 2002; 144: 1026–35.
14. Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 2006; 41 (7): 647–54.
15. Pai JK, Pischon T, Ma J, et al. Inflammatory markers the risk of coronary heart disease in men and women. N Engl J Med 2004; 35: 2599–610.
16. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
17. Chung M, Lichtenstein AH, Ip S, et al. Comparability of methods for LDL subfraction determination: A systematic review. Atherosclerosis 2009; 205: 342–8.
18. Varady KA, Lamarche B. Lipoprint adequately estimates LDL size distribution, but not absolute size, versus polyacrylamide gradient gel electrophoresis. Lipids 2011; 46 (12): 1163–7.
19. Banuls C, Bellod L, Jover A, et al. Comparability two different polyacrylamide gel electrophoresis methods for thee classification of LDL pattern type. Clin Chim Acta 2012; 413 (1–2): 251–7.
20. Hoefner DM, Hodel SD, O’Brein JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001; 47 (2): 266–74.